brigimadlin + itraconazole

**Brigimadlin + itraconazole** is an investigational combination of two drugs: brigimadlin, a highly potent oral MDM2–p53 antagonist being developed for the treatment of advanced/metastatic solid tumors with MDM2 amplification, and itraconazole, an oral antifungal agent that acts as a strong CYP3A4 inhibitor and is occasionally used in oncology for potential pharmacokinetic interactions or direct hedgehog pathway inhibition. Brigimadlin works by restoring p53 tumor suppressor activity in TP53 wild-type, MDM2-amplified cancers, leading to apoptosis and growth inhibition, and is under clinical evaluation in sarcoma, non-small cell lung cancer, and other solid tumors. Itraconazole is used to treat various fungal infections and can influence drug-drug interactions by inhibiting CYP3A4, potentially affecting the metabolism and plasma concentration of co-administered agents[2][4][5][6]. In this combination, there is no evidence of an approved clinical use, but coadministration could theoretically increase plasma concentrations of brigimadlin due to CYP3A4 inhibition by itraconazole, warranting careful monitoring for adverse effects and altered pharmacokinetics.

Other names

BI 907828BI907828BI-907828brigimadlinitraconazoleSporaNox